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Abstract
Timeliness of vaccinations is rarely part of monitoring in a routine immunization 
program. We reviewed infant immunization and conducted caregiver interviews 
in three regions in the Philippines from January to October 2016. We randomly 
selected thirty public health centers, one for each region. We defined timeliness of 
the receipt of antigen as within 4 weeks after the recommended age at vaccination. 
We assessed a total of 986 infants for timeliness of vaccination. The median age of 
receipt of vaccine was at 2.7 weeks (BCG), 10.1 weeks (Penta 1), and 21.7 weeks 
(Penta 3) compared to the recommended 0, 6, and 14 weeks of age, respectively. 
We found timely receipt only in 74.4% for BCG, 70.3% for Penta 1, and 39.1% for 
Penta 3 recipients. Thus, alongside declining immunization coverage, the infants in 
the Philippines had substantial delays in vaccine receipt.
Keywords Immunization · Routine immunization · Immunization program · 
Immunization schedule · Philippines
Introduction
Immunization is one of the most cost-effective public health interventions. According 
to the World Health Organization (WHO), immunization prevents between 2 and 3 
million deaths every year from diphtheria, tetanus, pertussis (whooping cough), and 
measles [1, 2]. The WHO established the Expanded Program on Immunization (EPI) 
in 1974 to reduce morbidity and mortality by improving vaccine availability globally. 
The program initially targeted six diseases: diphtheria, pertussis, tetanus, measles, 
poliomyelitis, and tuberculosis [2]. Subsequently, EPI introduced newer vaccines 
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into the program to lessen the burden of other vaccine-preventable diseases caused 
by hepatitis B virus, Haemophilus influenza type b (Hib), and Streptococcus pneumo-
niae. The EPI includes policies on evidence-based recommended vaccine schedules 
[2]. These schedules contain the age at which the child is most vulnerable to the dis-
ease and at which the vaccine can be given safely to achieve adequate protection.
Monitoring of immunization program performance has typically been assessed 
through measurements of vaccine coverage (the proportion of individuals who have 
received a vaccine by a benchmark age) regardless of the timing of administration 
[3, 4]. These do not take into account the timeliness, which detects adherence to 
vaccination schedules. Delays in immunization have potentially serious conse-
quences. First, children with delayed vaccination will be unprotected from the vac-
cine-preventable diseases at a time when they are most at risk [5]. Second, substan-
tial delays may contribute to diminished herd immunity or the indirect protection 
received by the unimmunized population when a large proportion is immunized [5]. 
Third, previous studies have demonstrated the association of delayed vaccination 
with increased risk of pertussis, measles, and Haemophilus influenzae type b infec-
tions and outbreaks [5–10]. Fourth, delays increase the risk of failing to achieve full 
immunization of the child [5, 11, 12]. Thus, adherence to immunization schedules 
or timeliness of vaccination is also an important indicator of a successful national 
immunization program aside from vaccine coverage.
In the Philippines, only one published study examined the timeliness of immu-
nization [13]. The Philippines EPI had also been monitoring program implementa-
tion using vaccine coverage rates. In this study, we explored the timeliness of infant 
immunization and assess factors that may be associated with delayed vaccination 
using immunization records review and caregiver interviews.
Methods
Study setting and population
The Philippines is an archipelago with three major island groups (Luzon, Visayas, 
and Mindanao). The healthcare system is divided into 17 autonomous regional 
health offices charged with implementation of the immunization program. The coun-
try follows the recommended schedule by the Expanded Programme of Immuniza-
tion by the World Health Organization (WHO).
We analyzed the immunization records and caregiver interviews from a study 
conducted on the introduction of inactivated poliovirus vaccine (IPV) in the Philip-
pines [14]. The study collected immunization data on the following vaccines: Bacil-
lus Calmette-Guérin vaccine (BCG) birth dose, Hepatitis B vaccine (HepB) birth 
dose, pentavalent vaccine series (includes vaccines for diphtheria, whole-cell per-
tussis, HepB, and Hib, referred to as Penta in this study), pneumococcal conjugate 
vaccine (13-valent) (PCV13) series, oral polio vaccine (OPV) series, and inacti-
vated poliovirus vaccine (IPV). Because the immunization records did not contain 
Timeliness of childhood vaccinations in the Philippines 
any sociodemographic variables about the infants, we supplemented data collection 
with a structured interview and investigated factors affecting vaccine timeliness.
We conducted the study from January to October 2016 in three regions, rep-
resenting the three major island groups in the country: Luzon (Region 3), the 
Visayas (Region 6), and Mindanao (Region 10) (Fig. 1). The Philippine Depart-
ment of Health selected these three regions for pilot implementation of IPV 
introduction. Region 3 (Central Luzon Region) has a population of 11,124,400, 
with an infant population (< 1-year-old) of 300,300. It has 119 public health cent-
ers (PHCs) that serve the 7 provinces and 2 cities. Region 6 (Western Visayas 
Region) has a total population of 8,317,800, with an infant population of 224,600. 
It has 147 PHCs that serve the 6 provinces and 2 cities. Region 10 (Northern 
Mindanao Region) has a total population of 4,799,700, with an infant population 
of 129,600. It has 122 PHCs that serve the five provinces and 2 cities.
Field data collection
We calculated the sample size of PHCs for each region to test whether there was 
a 5% or greater decrease in the proportion of eligible infants receiving all the 
Fig. 1  Location of the three 
study sites (Region 3 Central 
Luzon, Region 6 Western 
Visayas, and Region 10 North-
ern Mindanao)
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recommended injectable vaccines with the PHCs as the primary unit of analysis. 
We determined 29 PHCs are needed to attain a power of 81%. We selected 30 
PHCs by simple random sampling from a list in each region.
We deployed field staff already trained for interviews, data collection, and 
data entry in accordance with the guidelines set by the study team. We carried 
out additional training for interview conduct in vernacular language to maximize 
comprehension by interview respondents. We scheduled our staff to visit a PHC 
on an immunization day for data collection. An immunization day is a specific 
day within the week when infants received their immunizations in a PHC.
For each PHC, we prospectively reviewed the records of at least 10 infants at 
the site on an immunization day. If fewer than 10 infants came that day, a staff 
member made a return visit to comply with the minimum number. We interviewed 
5 caregivers selected through convenience sampling on each immunization day in a 
PHC. We determined that caregivers would be eligible for interviews if ≥ 18 years 
and if she or he brought an infant for that child’s 14-week visit. If the study team 
did not achieve 5 interviews, a member of the staff had to make a return visit until 
having completed the minimum number. We obtained Informed consent from the 
caregiver. We conducted standardized interviews in an isolated place to ensure the 
confidentiality of the responses by the caregivers. Field staff asked the questions in 
vernacular language—a native dialect or form of speech of specific people or a spe-
cific region—and responses were recorded and classified for data analysis.
We collected the data using password-protected Android tablets with a pre-
installed application developed for the study. The study team tabulated the 
answers in real time and sent them to a secured server at the study institution. 
We conducted data quality checks in real time to ensure accurate data entry in 
the application. We provided immediate feedback for any data inconsistencies 
and resolved these issues within the day of the visit.
The previous study focused on the introduction of IPV given at the 14th week 
visit and hence had data limited up to that visit only. In addition, infants may have 
received different vaccine dose numbers in those given in a series at that visit, 
depending on caregiver or healthcare provider preference or availability of vac-
cines during the previous visits. For example, an infant may have received Penta 
1, PCV13 2, OPV 3, and IPV at this visit if s/he had not yet received these vac-
cines. One year after the survey, in September 2017, the study staff revisited the 
PHCs to gather vaccination information on the enrolled infants from the immuni-
zation records retrospectively. The PHC revisit determined whether these infants 
received all the recommended vaccines. We merged these data with the original 
dataset from the previous study to determine the timeliness of vaccination.
Definition of timely receipt and timely completion of vaccination
In this study, we used the recommended age of vaccine receipt as defined by the 
Philippine EPI. For infants < 6 months old, the EPI recommends these doses at 
birth (BCG and HepB) and visits at 6 weeks of age (Penta/PCV13/OPV dose 1), 
at 10  weeks (Penta/PCV13/OPV dose 2), and at 14  weeks (Penta/PCV13/OPV 
dose 3 and IPV). Based on this, we defined timely receipt for each vaccine, as 
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the receipt of the vaccine within 4  weeks after the recommended age, and we 
defined ‘delays’ as receipt of the recommended dose for > 4 weeks after the rec-
ommended age. Thus, we set age cut-off for delays at 4 weeks for BCG and HepB 
(recommended at birth), 10 weeks for Penta/PCV13/OPV dose 1 (recommended 
at 6 weeks), 14 weeks for Penta/PCV13/OPV dose 2 (recommended at 10 weeks), 
and 18 weeks for Penta/PCV13/OPV dose 3 and IPV (recommended at 14 weeks).
We defined ‘complete vaccination’ as an infant receiving all the vaccines 
included in the study before 6 months of age. This is an arbitrary cut-off in most 
immunization programs. Since maternal antibodies in an infant disappear at 
6 months, most programs aim to complete the primary infant series before this age.
Data analysis
We summarized the baseline characteristics of the study population by frequency 
and proportion for the categorical variables. We computed for the age of receipt of 
vaccine for each child (expressed in weeks) by using their respective birthdate and 
corresponding dates of vaccination. We compared the mean age of receipt to the rec-
ommended schedule in the EPI using one-sample t test. Also, we used time-to-event 
analysis to determine the proportion of children having received the vaccination at 
each time point, as previously described in a study [15, 16]. To assess timely com-
pletion, we determined the number of infants who received all the vaccines (BCG, 
HepB, Penta 1, and Penta 3) on or before 6 months of age. We used logistic regres-
sion to compute the odds ratio on the timely completion and sociodemographic 
determinant. The sociodemographic variables included were caregiver sex (male or 
female), relationship to the infant, age group, number of children, and level of edu-
cation. We also used the frequency of immunization days of PHCs as an additional 
variable in the logistic regression. As a sensitivity analysis, we performed multilevel 
logistic regression to determine if clustering of data had occurred because of the 
enrollment by regions. For statistical analysis, we used STATA 15.1 (STATA Corp, 
Texas, US) with two-tailed tests, and considered a P value < 0.05 significant.
Ethical consideration
Ethical clearance was obtained from the University of the Philippines Manila Research 
Ethics Board (UPM-REB-2015-349-01) and the WHO Regional Office of the Western 
Pacific Ethical Review Committee (2015.25.PHL.5.EPI) prior to the study conduct.
Results
Study population and baseline demographic data
We assessed a total of 986 infant records to determine the timeliness of 
vaccination, of which 465 (47.2%) had been paired with interview data 
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(sociodemographic factors). There was an equal distribution of infants across the 
different regions: 328 infants (33.3%) were from Region 3, 316 infants (32.0%) 
from Region 6, and 342 infants (34.7%) from Region 10. Most of the infant car-
egivers were females (97.8%) belonging to the 25–34 age group (46.5%) and the 
majority were parents of the infants (88.2). Most had at least attended second-
ary school (92.5%). More than half of the PHCs give routine immunizations to 
infants on a weekly basis (Table 1).
Table 1  Demographic data of 
infants and infant caregivers, 
and frequency of immunization 
in the RHUs included in the 
study
PHC public health center
a These include the grandparent, aunt, uncle, and other caregivers
b Only female caregivers were asked regarding number of children in 
the household
c Reflects the frequency in infants whose caregivers were interviewed
Characteristics n (%)
Number of infants included
 Overall 986
 Region 3 328 (33.3)
 Region 6 316 (32.0)
 Region 10 342 (34.7)
Infant caregiver data











Number of  childrenb
 0–2 children 291 (62.6)
 3–4 children 122 (26.8)
 5 or more children 52 (11.4)
Level of education
 Attended primary/never attended school 35 (7.5)
 Attended secondary school 246 (52.9)
 Attended post-secondary school 184 (39.6)
Frequency of immunization in the  PHCc
 Weekly 301 (64.7)
 2–3 times per month 30 (6.5)
 Once a month 134 (28.8)
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Proportion of infants vaccinated and mean age of receipt of vaccines
The vaccine coverage rates and mean age of vaccine receipt overall and per region 
are shown in Table 2. At the end of follow-up, all infants received Penta 1, all OPV 
dose series, and IPV. The proportion of vaccinated infants exceeded 95% for the 
rest of the vaccines except HepB, at 88%. This was true for all regions excluding 
Region VI, where HepB coverage exceeded 95%. The mean ages of receipt of vac-
cines overall were beyond the accepted range of timely receipt in the study except 
for BCG, HepB, and OPV 1; a similar trend was observed in all 3 regions except for 
Penta 1 in Regions 3 and 6. All mean values were significantly different compared to 
the recommended age of vaccine receipt in the Philippine EPI (Table 2).
The proportion of infants who received the vaccines at the recommended age 
tended to decrease with vaccine doses in a series given at a later age, as shown 
in the Kaplan–Meier plots (Fig.  2). At birth, only 28.1% and 62.5% of infants 
received BCG and HepB birth doses, with a median age of receipt of 2.7 and 
0  weeks, respectively. In the primary infant series, only 3.7% of the children 
received Penta 1 at 6  weeks, with a median age of the receipt of 8.9  weeks of 
age and a delay of 2.9 weeks from the recommended age. Similarly, the propor-
tion of children who received a timely dose of Penta 3 was smaller at 0.5%. The 
median age of the population that received Penta 3 was 19.7 weeks, with a delay 
of 5.7  weeks from the recommendation (Fig.  2a). We observed a similar trend 
for the other vaccine series: only 3.3% and 3.9% of infants received PCV13 1 
and OPV 1 at 6 weeks, with a median delay of 3.0 and 2.4 weeks, respectively; 
and only 0.4% and 0.5% received PCV13 3 and IPV at 14 weeks, with a median 
delayed receipt of 7.7 and 5.6 weeks, respectively (Fig. 2b, c).
Timely receipt of vaccines and factors for delay in receipt of vaccines
Overall, the proportion of infants who received timely vaccination was low and 
below 90% for all vaccines analyzed (Tables  3). Similarly, this decreases with 
vaccine doses given in a series at a later age. Among the factors analyzed, a 
higher level of education and more frequent immunization schedule in the PHCs 
were associated with timely receipt of some of the vaccines. Infants of caregiv-
ers who attended secondary school were twice more likely to have infants in their 
care receive Penta 2 in a timely manner, while those whose caregivers attended 
post-secondary school were at least twice more likely to receive Penta 2, Penta 3, 
and OPV 3 compared to those with lower levels of education. We observed a sim-
ilar trend with Penta 3 and PCV13 series among caregivers who attended second-
ary school, and with BCG, PCV13 2, OPV 3, and IPV among those who attended 
post-secondary school. Infants at PHCs that offered only a monthly immunization 
schedule were 40% and 50% less likely to receive BCG and HepB birth doses, 
respectively, compared to those with more frequent immunization schedules. On 
the contrary, we observed a trend towards lower chances of immunization with 
Penta 2, Penta 3, OPV 2, OPV 3, and IPV in infants brought to the PHCs by a 
female caregiver. 
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Fig. 2  Cumulative proportions of infants receiving vaccines by age in weeks. Data grouped as cumula-
tive proportion by a BCG, Hepatitis B, Penta 1, and Penta 3, b BCG, Hepatitis B, PCV13 1, and PCV13 
3, and c BCG, Hepatitis B, OPV 1, and IPV. Gray vertical line and boxed infant age (weeks) correspond 
to the recommended age of vaccine receipt. Gray area corresponds to the timely receipt as defined in this 
study (+ 4 weeks from recommended age). BCG, Bacillus Calmette-Guérin; HepB, Hepatitis B vaccine; 
IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; PCV13, pneumococcal conjugate vac-
cine (13-valent); Penta, Pentavalent vaccine
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Because we conducted the sampling by region, we performed a multilevel logistic 
regression model (Supplement Table 1) as part of our sensitivity analyses. In this 
analysis using regions as clusters, we found no statistically relevant factors for the 
delay in vaccine receipt.
Timely completion of immunization and factors for delayed completion
Of the 465 infants whose caregivers we interviewed, only 60.7% completed all the 
vaccines on time. We observed no statistically significant difference among caregiv-
ers’ age, sex, and educational status for the delayed completion of primary infant 
series. However, there was a trend towards delayed completion of immunization for 
infants in the care of females with 5 or more children in the household (Table 4). 
Table 4  Factors for timely  completiona of vaccines among infants whose caregivers were interviewed 
(N = 465)
BCG Bacillus Calmette-Guérin, HepB Hepatitis B vaccine, IPV inactivated poliovirus vaccine, OPV oral 
poliovirus vaccine, OR odds ratio, Penta pentavalent vaccine, PCV13 pneumococcal conjugate vaccine 
(13-valent)
a Timely completion of vaccines is defined as 3 doses of Penta, PCV13, and OPV, and one dose each of 
BCG birth dose, HepB birth dose, and IPV received within 6 months of age





Overall 282 (60.7) 183 (39.4)
Sex
 Female 274 (97.2) 181 (98.9) –
 Male 8 (2.8) 2 (1.1) 2.6 (0.2)
Relationship to infant
 Parent 245 (86.9) 165 (90.2) –
 Others 37 (13.1) 18 (9.8) 1.4 (0.3)
Age group
 18–24 years 93 (33.0) 66 (36.1) –
 25–34 years 127 (45.0) 89 (48.6) 1.0 (1.0)
 35 years and above 62 (22.0) 28 (15.3) 1.6 (0.1)
No. of children of female caregivers
 0–2 children 185 (65.6) 106 (57.9) –
 3–4 children 71 (25.2) 51 (27.9) 0.8 (0.3)
 5 or more children 26 (9.2) 26 (14.2) 0.6 (0.07)
Level of education
 Attended primary school/never attended 
school
119 (42.2) 65 (35.5) –
 Attended secondary school 145 (51.4) 101 (55.2) 1.4 (0.4)
 Attended post-secondary school 18 (6.4) 17 (9.3) 1.7 (0.1)
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Discussion
In most developing countries with problems on immunization coverage, informa-
tion about timeliness of immunization is not routinely collected. Instead, most coun-
tries monitor receipt of EPI vaccines at 12 or 24 months. In the Philippines, the EPI 
monitors ‘fully immunized children’ (FIC), defined as infants who received BCG, 3 
doses of DPT, 3 doses of OPV, 3 doses of HepB, and one dose of anti-measles vac-
cine before reaching 1 year of age [17]. However, this information does not provide 
insights into the extent to which vaccinations are administered on time. Our study 
revealed a substantial delay in the vaccine receipt for infants. The receipt of age-
appropriate vaccination was delayed with only 60.7% having completed vaccination 
at 6 months of age, and the mean age of vaccine receipt more than 4 weeks later than 
the recommended age (Penta 1 recommended at 6 weeks but received at 10.1 weeks, 
Penta 2 recommended at 10 weeks but received at 15.8 weeks, and Penta 3 recom-
mended at 14 weeks but received at 21.7 weeks).
We conducted the study after a 6- to 9-month pentavalent stockouts that 
occurred in 2015, and this resulted in untimely vaccination. Hence, the informa-
tion on the extent of the delays may not be representative of the current state 
of immunization. The World Health Organization and UNICEF estimated that 
repeated stockouts of vaccines contributed to a 15% point reduction in the Philip-
pine vaccine coverage for 2015, but the coverage marginally improved in the sub-
sequent years [18]. According to the 2017 National Demographic and Health Sur-
vey in the Philippines, only 70% of children aged 12–23 months received all the 
recommended vaccinations [19]. With low immunization coverage and delayed 
vaccination, a rise in the number of vaccine-preventable diseases appeared in the 
following years. Following the repeated Pentavalent vaccine stockouts in the Phil-
ippines, the WHO Representative Office of the Philippines reported a rise in the 
number of diphtheria cases in the country in 2015 [20]. The declining immuniza-
tion coverage also resulted in a measles outbreak in January 2019 [21] and the 
re-emergence of polio in September 2019 [22].
We identified further limitations in our study. First, our analysis is limited to 
primary infant immunization series (BCG, Hep B birth dose, DTwP-Hib-HepB, 
PCV, and OPV-IPV), which limits our analysis up to children 6 months of age. 
Equally important are the vaccination delays and coverage among older infants 
receiving measles and measles-mumps-rubella (MMR) vaccine. Studies have 
shown increased dropouts with increasing infant age [23, 24]. Second, we did 
not obtain other important maternal and social factors, namely, family income, 
distance from the PHCs, and other indicators for health-seeking behaviors. Third, 
our study has a small sample size, as we only included infants nested in a survey. 
A larger study to determine when children are being vaccinated in the Philippines 
will be useful for disease control and prevention efforts as well as for policymak-
ers, as this will provide information in ascertaining the appropriate vaccination 
schedule.
Our findings confirm delays in immunization in the Philippines that are simi-
lar to other developing countries [24–28]. The combination of low immunization 
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coverage and the delayed vaccine receipt among fully immunized children has 
negative repercussions on the control of vaccine-preventable diseases. These 
may result in a reduction in the benefits of the immunization program if there are 
delays in protecting high-risk children. With the delays, the age of the suscepti-
ble population becomes younger, and further disease transmission is shifted to a 
much younger population.
Our results explored the timeliness of vaccination in a country with a hugely 
growing and young population. In 2015, the Philippines added an additional 
injectable vaccine, IPV, to the schedule. Concomitant multiple injectable vac-
cination may have been a factor in changing and/or delaying scheduled immu-
nizations, and healthcare providers’ perceptions and attitudes may have been a 
major contributing factor [14]. The work schedule of each PHCs is a major driv-
ing factor. In some PHCs, immunization visits are scheduled once per week up to 
once per month. The latter precludes an increased number of opportunities for the 
infant to be vaccinated at PCHs with less frequent immunization sessions. This 
then translates to low immunization coverage and further delays in vaccination.
Another finding of our study is the delay in the receipt of BCG and HepB birth 
doses. For BCG, one of the most commonly cited reasons for disparity in the delay 
is the health worker’s striving to open a new vial only when a minimum number 
of vaccines/infants are reached to be cost-efficient. A BCG multidose vial is only 
available for 6 h after reconstitution, and the vial should be discarded if not used [1]. 
Thus, these providers advised caregivers to go to the nearest immunization facil-
ity for the infant to receive the vaccine in order to minimize the vaccine wasting. 
This practice is not allowed in the current immunization guidelines. The guideline 
requires health workers to open vials and vaccinate infants regardless of whether 
the minimum number of vaccines/infants is reached. This practice is not a problem 
with HepB vaccine as the multidose vial can be used within 28 days after opening, 
and the utility of each vial can be maximized easily. Disparities in Hepatitis B delays 
are brought about by difficulties in reviewing records. The vaccine is usually given 
in birthing facilities while the immunization registries and immunization cards are 
being distributed in immunization facilities [29]. PHCs serve as both birthing facili-
ties and immunization facilities, but this practice may differ across all regions.
Conclusion
We have updated the data on the timeliness of immunization for infants in the Phil-
ippines and explored delays in vaccinations that could be common for low-middle 
income countries with a huge vaccine target population. With the looming threat 
of vaccine hesitancy that may cause more delays in vaccination or even vaccine 
refusals, the gains achieved against vaccine-preventable diseases are at risk [30]. 
Timeliness of receipt is crucial to confer early protection to an infant, to sustain 
herd immunity in the population, and to minimize the lost opportunity for vaccine 
completion. With the resurgence of vaccine-preventable diseases worldwide, we 
highlight the need for continued monitoring of vaccination, including delays in the 
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timing of vaccines. Timeliness of vaccine receipt is not only a surrogate measure 
for vaccine hesitancy in the population but has an impact on the control of vaccine-
preventable disease in the population.
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